title: [Therapeutic targeted approaches on androgen receptors in prostate cancer].
abstract: The treatment of metastatic prostate cancer since the 1940s is based on the consideration of oncogenic addiction to its androgen receptor (AR). The significant improvement in survival outcomes over the past decade depends not only on the development of effective cytotoxic chemotherapy but also new molecules targeting the AR or decreasing testosterone levels, even in case of castration-resistant cancer. In this review, we summarize the structure and function of the RA, the mechanisms of androgen suppression, the concept of resistance to castration, historical targeted treatment on the AR and those recently marketed as abiraterone acetate and enzalutamide.
authors.affiliation: Service d'oncologie, HIA Val-de-Grâce, boulevard Port-Royal, 75005 Paris, France. Electronic address: francoisregisferrand@gmail.com.
authors.forename: F-R
authors.initials: FR
authors.lastname: Ferrand
authors.affiliation: Service de médecine interne et cancérologie, HIA Desgenettes, boulevard Pinel, 69000 Lyon, France.
authors.forename: M
authors.initials: M
authors.lastname: Pavic
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002369:Castration / Q000379:methods; D055808:Drug Discovery / Q000379:methods; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000628:therapy*; D011944:Receptors, Androgen / Q000502:physiology*
chemical_list: C410798:AR protein, human; D018931:Antineoplastic Agents, Hormonal; D011944:Receptors, Androgen
keywords: Abiraterone; Abiratérone; Androgen receptor; Cancer de prostate; Enzalutamide; Prostate cancer; Récepteur aux androgènes